Regional Insights and Engagement Director, Lung, Central Rockies

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$231K-$254K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$93,011 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.1% - Faster than average

161% above the BLS role benchmark for marketing aggregate.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Marketing From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Regional Insights and Engagement Director, Lung, Central Rockies Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Regional Insights and Engagement Director, Central Rockies is a field-based position focused on working closely with Lung Cancer Key Opinion Leaders (KOLs) at select institutions and accounts within the defined geography. This person is a RevMed clinical and product expert for Key Opinion Leaders and ensures that cross-functional resources are made available as appropriate. In this role, you will be a member of the commercial development team, and you will work closely with marketing, medical affairs, field sales, insights and analytics and other cross functional colleagues. You will help inform brand strategy, develop and execute KOL tactics and you will be evaluated in conjunction with individual performance and brand KPIs. This role will cover major academic institutions, accounts, and the Lung Key Opinion Leaders located in the Central Rockies. Essential Duties: - Designs, executes, and implements significant national

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.